Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Insider transaction in Episurf Medical

Board member Laura Shunk has on 14 November 2018 bought 20,000 B-shares in Episurf Medical. Laura Shunk now owns 40,750 Class B-shares. For more  information, please contact:  Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed

Inhalation Sciences to present at Redeye Life Science Day, November 21 Stockholm

Inhalation Sciences’ CEO Lena Heffler’s presentation will also be streamed live. “The world-leading control and precision of our technology means lung scientists save crucial time and money in essential early-stage research. I look forward to showing investors how far we’ve already come.”The event will take place at Haymarket by Scandic, Hötorget in central Stockholm. Lena Heffler’s presentation will be in Sal 2, 08.20-08.40. All presentations at Redeye Life Science Day will be streamed live, beginning at 08.10. They can be followed on smartphone or computer at www.redeye.se/live/lsday-

Flexion Mobile Plc announces issue of US patent

Company is awarded patent for key aspects of its core technology in the USLondon, 16th of November, 2018 - Flexion Mobile Plc (“NASDAQ:FLEXM”), the London-based company that helps game developers maximise the growth potential of their Android games, today announced that the USPTO has issued patent no 10,127,035. The patent - SYSTEM AND METHOD TO MODIFY RUN-TIME BEHAVIOR OF AN APPLICATION BY MODIFICATION OF MACHINEREADABLE INSTRUCTIONS -  covers integral aspects of the technology that powers Flexion’s service offering. Jens Lauritzson, CEO of Flexion Mobile, commented: “We are proud

Nordic Nanovector ASA: Increased share capital following exercise of employee share options

Oslo, Norway, 16 November 2018. A individual participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share. Each free-standing warrant gives the right to receive one share in the Company. Following exercise of the 300,000 free-standing warrants, the

Axactor adds another forward flow agreement with a new client in Norway

Oslo, November 16th 2018 Axactor Norway has complemented their existing forward flow agreements, by adding a new large financial institution to the list of clients it acquires fresh NPL volumes from. The contract period is 18 months, with an option to extend for a further 6 months. The total expected outstanding balance sold will be up to 22 mEUR across 12.500 claims. “Norway continues to succeed in adding new volumes from high quality sellers. This contract when combined with the existing volumes, will help us to deliver significant growth in Norway in 2019.” says Stina Koren,

Basware response to media speculation

Basware Corporation, stock exchange release, November 16, 2018 at 11:05 a.mBasware refers to the recent media speculation about a takeover approach and confirms that it has been approached with a non-binding and highly conditional indicative proposal for a possible tender offer for the entire share capital of Basware (the “Indicative Proposal”). The Indicative Proposal is subject to a number of pre-conditions including, but not limited to, securing of appropriate financing, satisfactory completion of due diligence and a recommendation from the Board of Directors of Basware. Completion of

Resurs Bank planning to sell delinquent receivables

Resurs Bank, a wholly owned subsidiary of Resurs Holding, has entered into forward flow agreements with credit management companies Alektum Group, Axactor and Lowell, enabling them to recover some of the bank’s delinquent receivables in Sweden and Norway. The first transfer is expected to take place in January 2019. The transfers are expected to have a positive impact on Resurs Bank’s capital requirements, liquidity and earnings.Some of Resurs Bank’s receivables that are more than 120 days past due will be sold to the credit management companies. The total quantity of outstanding debt

Resurs Bank planning to sell delinquent receivables

Resurs Bank has entered into forward flow agreements with credit management companies Alektum Group, Axactor and Lowell, enabling them to recover some of the bank’s delinquent receivables in Sweden and Norway. The first transfer is expected to take place in January 2019. The transfers are expected to have a positive impact on Resurs Bank’s capital requirements, liquidity and earnings.Some of Resurs Bank’s receivables that are more than 120 days past due will be sold to the credit management companies. The total quantity of outstanding debt under the agreements is SEK 550 million and the

Telia Company acquires Finnish ICT service company Ainacom Oy

Telia Company acquires AinaCom Oy, a Finnish provider of ICT services to enterprise customers. The acquisition will further strengthen Telia Company’s position as a leading national partner for ICT services in Finland.AinaCom Oy provides business customers with voice, mobile, network and IT solutions, including connections and has approximately 60 employees. In 2017 AinaCom reported net sales of EUR 15.5 million and an adjusted EBITDA of minus EUR 0.4 million.   Telia Company expects to complete the transaction on December 3, 2018.   In 2014, Telia Company acquired AinaCom's

Inhalation Sciences helps leading research on breathing in metal nanoparticles: Will dissolution testing become mandatory?

More industrial processes than ever are using nanoparticle. Yet many questions remain about the health consequences of inhaling them. Not just in our lungs but at a cellular, even genetic level.  Karolinska Institutet doctoral researcher Sarah Mccarrick is using Inhalation Sciences equipment to test how copper and copper oxide nanoparticles impact us.Nanoparticles offer a world of advantages to industrial process manufacturers. But what happens when we breathe them in? Inhalation researcher Sarah Mccarrick has joined the Institute of Environmental Medicine team at Karolinska Institutet,

Extend the service life of your tires: store them in a cool, dry, and dark place

The storage location of your tires matters. According to experts, the correct storage temperature is the most important factor. You can also extend the service life of your tires by protecting them against moisture, chemicals, and UV radiation. A tire hotel is the easiest choice. Should I store my summer tires in the garage, basement, on the balcony, or outside next to the house? According to Martin Dražík, Product Manager for Nokian Tyres Central Europe, the storage temperature is the most important factor.  – Back in the day, some people used to store tires nearby their central

Notice Release of Report for Q3 2018

2018-11-16 Please note that the report for the third quarter ended September 30, 2018 will be released on the 26th of November, 2018 at 9:00 am CET.An international conference call for investors and analysts will be held on November 28, 2018 at 3:00 pm CET. The dial-in number is: Standard International Access +44 (0) 20 3003 2666 Stockholm +46 (0) 8 50520424 New York +1 646 843 4608 Washington DC Local number +1 202 204 1514 The meeting code is Corral Q3. For further information, please contact:Magdalena PatrónInvestor Relations ManagerTel: + 46 (0)10 450 10 00

DreamHack Leipzig lowers expo age restriction to 12 years and above

Flashing screens, thrilling events, and an exciting atmosphere – from 15 to 17 February 2019, DreamHack Leipzig is the gaming community’s Mecca once again. Visitors can expect a varied three-day program of eSports tournaments, cosplay, community stars, and a large DreamExpo. As of 2019, the latter will also be of interest to young gamers. While admission was previously restricted to guests 16 years and older, this year – thanks to the development of a new hall concept – visitors 12 years and older can also attend the exhibition. “The DreamHack Leipzig is now open to visitors aged

Citi Launches Direct Custody and Clearing Services in Norway

Launch consolidates Citi’s leadership with the industry’s largest proprietary custody network in the region and globally. Opening highlights commitment to the Nordics as Citi celebrates its 45th Anniversary in Norway. Oslo, London – Citi will begin offering Direct Custody & Clearing (DCC) services to clients in Norway, starting mid-November.  The new offering expands Citi’s proprietary DCC network to over 60 markets globally including 37 markets across Europe, the Middle East and Africa (EMEA).DCC plays an integral role in the capital markets by providing clearing and settlement services

Exercise period for BrainCool’s warrants, TO1, 21 November – 4 December 2018

As part of our financing strategy and the agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of November 21 to December 4, 2018, holders of TO1 Warrants can exercise the Warrants and subscribe for new shares. One (1) TO1 warrant can be exchanged for one (1) share, at a price of SEK 13.93. The current market price is below the exercise price. Unless the market price exceeds the exercise price, it is not beneficial to subscribe in the current exercise period. Therefore, the application form has not been

Interim report January – September 2018

Third quarter in brief · SyntheticMRs had sales growth of 46% in the third quarter compared to the previous year. · Net sales amounted to SEK 11,2 million (7,7) · Operating profit increased to SEK 5,4 million (2,2) · Profit for the period amounted to SEK 4,2 million (1,7) · Earnings per share amounted to SEK 1,04 (0,42) · Sales for rolling 12 months amounted to SEK 46,1 million (31,6) Nine months in brief · Net sales amounted to SEK 33,0 M (22,5), which means sales growth of 47% · Operating profit increased to SEK 13,4 M (5,7) · Profit for the period amounted

The University Hospital, Vejle Hospital and 2cureX have received approval to start a clinical trial in pancreatic cancer

2cureX AB (“2cureX”) is pleased to announce that we together with our clinical partner Vejle Hospital have received approval to launch a clinical trial in metastatic pancreatic cancer. Patients will be included in the trial from November 2018 to December 2020. Patient outcome data will be collected until December 2023. The study is an investigator-initiated trial where costs are shared between the hospital and 2cureX. IndiTreat® is now being clinically validated in three major cancer diseases (colorectal, ovarian and pancreatic cancers).Pancreatic cancer is globally one of the most common

ChromoGenics delivers I-Window glass to Kungsleden for an order value of approximately SEK 275 thousand

ChromoGenics AB (publ) has signed an agreement with Kungsleden to deliver I-Window glass to Kvartersakuten Mörby in Stockholm for a retro-fit project where existing glass is replaced with maintenance-free I-Window glass.The project is a retro-fit project of about 60 sqm I-Window glass including construction work with planned delivery in the fourth quarter of 2018. Kungsleden chose to upgrade the property's windows to maintenance-free I-Window glass instead of traditional outside solar control systems. In the premises, a healthcare center conducts its activities. "We are proud that

Sabine Helterhoff appointed new BU President for Bonava Germany

Sabine Helterhoff is appointed President of Business Unit Bonava Germany. Sabine Helterhoff is currently Head of Legal and Investor Business for Bonava Germany. Sabine will take up the new position on 1 January 2019, she succeeds Olle Boback who will be retiring.- It pleases me that we now have appointed a new BU President for Bonava Germany. With Sabine Helterhoff’s broad knowledge within the housing developer industry and her 18 years in the company as Head of Legal and Investor Business in Germany, Sabine Helterhoff will make an excellent successor to Olle Boback, says Joachim Hallengren,

Jays announces partnership with Emart in South Korea

Jays branded fixture at Emart flagshipstore in Yeongdeungpo [Jag tror vi behöver en bra bas i Sydkorea. Vi får denna chansen] Jag tror vi behöver en bra bas i Sydkorea. Vi får denna chansen Jays announces partnership with Emart in South Korea  General Press releaseSwedish audio product developer Jays Group AB (publ) is partnering with Emart, leading technology retailer with 148 stores in South Korea. Jays Group AB (publ) announces a new partnership in South Korea together with Emart. The cooperation which started in Q4 2018 involves Jays full range of products in 30 APRs (

Dignitana AB (Publ) Announces Rights Issue and Directed Equity Issue

Dignitana AB to carry out new issues of approximately SEK 31.6M in a directed issue of approximately SEK 5.8M, a fully guaranteed rights issue of SEK 24.3M with preferential right for existing shareholders and another directed rights issue offsetting the guarantee fee of approximately SEK 1.4M.The Board of Directors of Dignitana AB (“Dignitana” or the “Company”) decided today to carry out a capitalization of up to SEK 31.6M in a directed rights issue of approximately SEK 5.8M, a fully guaranteed rights issue of SEK 24.3M with preferential right for existing shareholders and another directed

AstraZeneca provides update on Phase III MYSTIC

This announcement contains inside information 16 November 2018 07:00 GMT AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer AstraZeneca and MedImmune, its global biologics research and development arm, today announced final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinziand tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) platinum-based chemotherapy in

There are no items matching the current filter
There are no more items matching the current filter
Back to top